← ANALYST RATINGS · TIPRANKS
Entrada Therapeutics Inc (TRDA): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy1 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $4.37.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $25.00 | Buy | +472.1% | Reiterated | 15.10.26on TipRanks Oct 16 03:25 | +4.8%next day −7.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 → $5.00−9.1% | Hold | +14.4% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.50 → $4.50−18.2% | Hold | +3.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.50 → $4.50−18.2% | Hold | +3.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $5.50 → $4.50−18.2% | Sell | +3.0% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 → $5.00−9.1% | Hold | +14.4% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.50 → $5.00−9.1% | Hold | +14.4% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $23.00 | Buy | +426.3% | Reiterated | 03.09.26on TipRanks 07:30 | −2.8%next day −0.2% · 5 days −4.0% | ↗ |
| Boobalan Pachaiyappan★★★★★★★★★★#11894 · hits 38% · avg −7.5% | Roth MKM | $10.00 → $11.00+10.0% | Buy | +151.7% | Reiterated | 12.08.26on TipRanks 15:10 | +8.7%next day −3.6% · 5 days +1.9% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | — | Hold | — | Reiterated | 10.08.26on TipRanks 06:27 | +1.2%next day +1.6% · 5 days +5.4% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 05.08.26on TipRanks 16:15 | −2.5%next day −0.6% · 5 days +7.2% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $20.00 → $17.00−15.0% | Buy | +289.0% | Reiterated | 05.06.26on TipRanks Jun 8 07:11 | −6.4%next day −2.0% · 5 days +0.8% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 07.05.26on TipRanks 13:35 | −57.0%next day −1.0% · 5 days −2.6% | ↗ |
| Yanni Souroutzidis★★★★★★★★★★#10612 · hits 25% · avg −16.7% | Cantor Fitzgerald | — | Buy | — | Initiated | 01.04.26on TipRanks 06:35 | +6.1%next day −2.5% · 5 days +0.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Entrada Therapeutics Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $17.00 at a price of $6.35 (+167.7%); now: $19.67 at $4.37 (+350.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 1 | 1 | 0 | 0 |
| Buy | 4 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.01 (from $-1.22 to $-0.62). Last quarter: $-1.01.
Sales
Next quarter’s sales estimate — $2M (from $0M to $10M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Entrada Therapeutics Inc
- CEO: Dipal Doshi
- Employees: 152
- One Design Center Place, Boston, MA, 02210, US
- www.entradatx.com
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 148 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗